Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results
Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $96
Wedbush Maintains Neutral on Gossamer Bio, Lowers Price Target to $32
Gossamer Bio: Q3 Earnings Snapshot
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio Q3 EPS $(7.36) Misses $(3.68) Estimate, Sales $38.431M Beat $12.148M Estimate
Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks
Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160
Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial Hypertension
HC Wainwright & Co. Maintains Buy on Gossamer Bio, Raises Price Target to $90
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Gossamer Bio Announces 1-For-80 Reverse Stock Split, Effective September 10
Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?
Gossamer Bio announces $250m in funding to advance seralutinib
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.